Showing 1 posts of 1 posts found.
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
Artificial hearts: a century of innovation
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
MHRA awards Innovation Passports to liver cancer and dementia medicines
Scottish NHS hospital adopts light-activated therapy to reduce surgical infections